Encyclopedia

Leukemia

Also found in: Dictionary, Medical, Acronyms, Wikipedia.
(redirected from Prolymphocytic leukemia)

leukaemia

(esp US), leukemia
an acute or chronic disease characterized by a gross proliferation of leucocytes, which crowd into the bone marrow, spleen, lymph nodes, etc., and suppress the blood-forming apparatus
Collins Discovery Encyclopedia, 1st edition © HarperCollins Publishers 2005

leukemia

[lü′kē·mē·ə]
(medicine)
Any of several diseases of the hemopoietic system characterized by uncontrolled leukocyte proliferation. Also known as leukocythemia.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
The following article is from The Great Soviet Encyclopedia (1979). It might be outdated or ideologically biased.

Leukemia

 

a tumorous systemic disease of hematopoietic tissue in which the impairment of hematopoiesis is manifested by a proliferation of immature pathological cellular elements, both in the hematopoietic organs proper and in other organs (the kidneys, vascular walls, neural pathways, skin, and so forth). The disease is rare (one case per 50,000 population).

Leukemias are grouped into the spontaneous leukemias, the causes of which have not been determined; radiation leukemias, caused by ionizing radiation; and leukemias caused by certain chemical (leukemogenic, or blastomogenic) substances. Leukemogenic viruses have been isolated from a number of animals suffering from leukemia (chickens, mice, rats, dogs, cats, cattle). A viral etiology has not been proved for human leukemia. Leukemias are divided into reticulosis, hemocytoblastosis, myeloid leukemia, erythromyelosis, and megakaryocytic leukemia, depending on cellular morphology (the predominance of particular elements).

Depending on the extent of the increase in the total number of leukocytes and the “flooding” of the blood with immature, pathological cells (normally not found in the blood), leukemias are classified as leukemic, in which the number of pathological leukocytes found in 1 cu mm of blood totals tens of thousands, hundreds of thousands, and even millions, instead of the normal 6,000–10,000; subleukemic, in which the number of pathological leukocytes does not exceed 15,000–25,000 per cu mm; leukopenic, in which the number of leukocytes in the blood decreases but with which pathological, “leukemic” cells may also be present; and aleukemic, in which the number of leukocytes in the blood does not increase and no immature, pathological forms are present. Aleukemic leukemias that progress at a pronouncedly malignant rate are usually called reticuloses.

Leukemias may be acute or chronic. Acute leukemias are marked by a rapid course with a blood picture characterized by an abrupt breakdown of hematopoiesis at a given stage, resulting in the failure of the most immature forms, or blasts, to develop into mature blood cells. The hemogram is marked by some degree of “blastemia,” with an insignificant number of mature leukocytes and an absence of transitional forms. As a rule, acute leukemia occurs with fever, marked anemia, hemorrhagic diathesis, ulcerations, and necrosis in various organs.

Chronic leukemias are classified, according to the aspect of hematopoiesis disturbed, as chronic myelosis (myeloid leukemia), lymphadenosis (lymphocytic leukemia), histiomonocytic leukemia, erythromyelosis, and megakaryocytic leukemia. Chronic myelosis, the most common, is characterized by hyperplasia (proliferation) of the elements of bone-marrow, or myeloid, hematopoiesis, both in the bone marrow proper (the fat marrow of the long bones being replaced by red hematopoietic marrow) and in the spleen (which enlarges significantly), liver, and lymph nodes (where normal lymphoid tissue is replaced by pathological myeloid elements). The blood is flooded with immature, mature, and transitional granular leukocytes.

Chronic lymphadenosis usually follows a protracted but comparatively benign course. The disease develops gradually, chiefly with enlargement of the lymph nodes, although enlargement of the spleen and liver sometimes becomes predominant. Normal myeloid bone marrow is replaced by lymphoid marrow. The blood is flooded with lymphocytes (predominantly mature). Blasts appear during exacerbations. Anemia gradually develops, because lymphoid infiltrates depress the normal hematopoietic function of the bone marrow and because the pathological lymphocytes lose the function of immune competence and manufacture autoaggressive antibodies (in particular, antierythrocytic antibodies, which cause hemolysis). In some cases, the pathological lymphocytes produce antithrombocytic antibodies, which cause thrombocytopenia and hemorrhages. Exacerbations of chronic leukemia are marked by elevated temperature, sweating, wasting, bone pains, increasing general weakness, anemia, and hemorrhagic diathesis.

The pathogenesis (that is, the mechanism of development) of leukemia has not been studied adequately; however, it is believed that the disease begins with cellular mutations that appear in the body after exposure to a variety of exogenous (viral, radiation, chemical) and endogenous leukemogenic agents (in particular, agents that appear with an impairment of tryptophan metabolism). The mutagenic action of these agents disrupts the normal development of the hematopoietic cells, and anaplasia sets in (that is, the loss by the cells of their capacity for normal differentiation and development into mature leukocytes). The accumulation of immature, physiologically deficient cells, manifested in tumorlike growths and leukemic invasion of various organs, results in systemic intoxication and wasting and in dysfunction of the affected organs and systems. Because of the more or less marked decrease in the number of mature, functionally adequate leukocytes and thrombocytes (depending on the form of leukemia and the phase of its development), the course of leukemia is accompanied by a decline in systemic and local immunity. This is manifested in the development of severe infectious, septic, necrotic, ulcerative, and hemorrhagic complications. Leukemic invasion, or metaplasia, of the bone marrow usually gives rise to anemia; this is further aggravated by hemorrhages associated with the thrombocytopenia and intensified hemolysis that result from the autoimmune complications.

Acute leukemia and exacerbations of chronic leukemia are treated in a hospital (preferably one that specializes in blood diseases) where the blood and bone marrow can be monitored. Combinations of cytostatic agents and steroid hormones are used. Sometimes radiotherapy, blood transfusions, supporting and antianemic agents, and multiple vitamins are prescribed. Antibiotics are administered to prevent or control infectious complications. During remissions, acute and chronic leukemia patients receive supporting treatment in specialized hematological departments of polyclinics. In accordance with present regulations in the USSR, all leukemia patients receive all prescribed drugs free of charge.

REFERENCES

Dul’tsin, M. S., I. A. Kassirskii, and M. O. Raushenbakh. Leikozy. Moscow, 1965.
Kassirskii, I. A., and G. A. Alekseev. Klinicheskaia gematologiia, 4th ed. Moscow, 1970.
G. A. ALEKSEEV
The incidence of leukemia in mammals is recorded in many countries where livestock is raised on a large scale, including the USA and countries of Europe. In the USSR, leukemia is registered in the Baltic Region, the Northern Caucasus, on some farms in the European USSR, and in Siberia. Among the theories advanced to explain the occurrence of leukemia in domestic animals—radiation, chemical, genetic, hormonal, viral, and viral-genetic—the last has gained the widest acceptance. However, the matter has not been conclusively settled. Cattle, horses, swine, dogs, cats, rats, mice, and other mammals of all breeds (especially older animals), as well as man, contract the disease. No clear and direct relationship has been established between leukemia contracted by man and the leukemia found in farm animals (M. P. Khokhlova; 1968, 1971). The disease may go on for months or years without perceptible clinical symptoms. Diagnosis is based on the results of blood tests. Treatment is considered to be inexpedient. Prevention entails the organization of efforts to keep the disease away from healthy farms and of properly maintained zootechnical documents.
Avian leukosis occurs in countries with advanced poultry farming and causes great economic damage. The causative agent of the disease is a virus with a large number of strains. The disease occurs mostly in chickens more than four months of age; less commonly, it is found in turkeys, guinea hens, ducks, and geese. Cases have also been recorded in pigeons, canaries, parrots, and other birds. Diseased birds and virus carriers are the source of the causative agent. Infection takes place mainly through the eggs. There are no characteristic clinical symptoms of the disease, which is diagnosed on the basis of laboratory tests and pathomorphological examination. No treatment has been developed. Preventive measures include the building up of pedigreed flocks with animals from leukosis-free farms only, the strict isolation and good care of the young animals, proper feeding, and the breeding of fowl resistant to the disease.

REFERENCES

Vasil’ev, N. T., N. V. Rumiantsev, and V. Z. Cherniak. Leikozy sel’skokhoziaistvennykh zhivotnykh. Moscow, 1966.
Problemy leikozov. Moscow, 1967.
Khokhlova, M. P. “Izuchenie epidemiologii leikozov cheloveka v sravnitel’nom aspekte.” In Materialy II simpoziuma po leikozu krupnogo rogatogo skota. Tallinn, 1971. Pages 19–35.

A. M. LAKTIONOV

The Great Soviet Encyclopedia, 3rd Edition (1970-1979). © 2010 The Gale Group, Inc. All rights reserved.
Mentioned in
References in periodicals archive
Thaler et al., "Pentostatin in prolymphocytic leukemia: phase II trial of the european organization for research and treatment of cancer leukemia cooperative study group," Natl Cancer Inst, vol.
The blood samples with abnormal results included various clinical conditions, such as acute myeloid leukemia, acute lymphoblastic leukemia/lymphoma, myelodysplastic syndrome, myeloproliferative neoplasms, chronic lymphocytic leukemia, other mature B-cell lymphomas, plasma cell neoplasms, T-cell prolymphocytic leukemia, infections, chronic inflammatory conditions, leukopenia, and anemia (Table 1).
Food and Drug Administration for three indications: T-cell non-Hodgkin's lymphoma, including CTCL; chronic lymphocytic leukemia (CLL) and related leukemias including prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia; and for treatment of acute lymphoblastic leukemia (ALL).
Seventeen cases (68%) were T-cell and NK/T-cell lymphomas, including 5 NKTCLs, 5 angioimmunoblastic T-cell lymphomas; 3 peripheral T-cell lymphomas, unspecified; 2 anaplastic large cell lymphomas; 1 T-cell prolymphocytic leukemia; and 1 blastic plasmacytoid dendritic cell neoplasm (blastic NK-cell lymphoma).
Copyright © 2003-2025 Farlex, Inc Disclaimer
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.